Journal
CANCERS
Volume 14, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/cancers14071771
Keywords
clonality; diversity; immune-checkpoint inhibitor; neoantigens; TCR; TILs; tumour-associated antigens
Categories
Funding
- Fundacion Contigo Contra el Cancer de la Mujer
Ask authors/readers for more resources
The study of TCR repertoire in cancer patients is important for understanding the anti-tumoural response, predicting prognosis, and determining response to immune checkpoint inhibitor therapies. The TCR repertoire is influenced by various factors and can provide valuable insights for modulating immune responses and predicting outcomes.
Simple Summary The TCR is the T cell antigen receptor, and it is responsible of the T cell activation, through the HLA-antigen complex recognition. Studying the TCR repertoire in patients with cancer can help to better understand the anti-tumoural responses and it has been suggested to have predictive and or/prognostic values, both for the disease and in response to treatments. The aim of this review is to summarize TCR repertoire studies performed in patients with cancer found in the literature, thoroughly analyse the different factors that can be involved in shaping the TCR repertoire, and draw the current conclusions in this field, especially focusing on whether the TCR diversity-or its opposite, the clonality-can be used as predictors or prognostic biomarkers of the disease. T cells play a vital role in the anti-tumoural response, and the presence of tumour-infiltrating lymphocytes has shown to be directly correlated with a good prognosis in several cancer types. Nevertheless, some patients presenting tumour-infiltrating lymphocytes do not have favourable outcomes. The TCR determines the specificities of T cells, so the analysis of the TCR repertoire has been recently considered to be a potential biomarker for patients' progression and response to therapies with immune checkpoint inhibitors. The TCR repertoire is one of the multiple elements comprising the immune system and is conditioned by several factors, including tissue type, tumour mutational burden, and patients' immunogenetics. Its study is crucial to understanding the anti-tumoural response, how to beneficially modulate the immune response with current or new treatments, and how to better predict the prognosis. Here, we present a critical review including essential studies on TCR repertoire conducted in patients with cancer with the aim to draw the current conclusions and try to elucidate whether it is better to encounter higher clonality with few TCRs at higher frequencies, or higher diversity with many different TCRs at lower frequencies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available